Patents Assigned to Juno Therapeutics, Inc.
  • Publication number: 20220008465
    Abstract: Provided are methods for treatment and uses involving the administration of doses of engineered T cells for treating subjects with disease and conditions such as certain B cell malignancies, and related methods, compositions, uses and articles of manufacture. The engineered cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the disease or condition is acute lymphoblastic leukemia (ALL) or non-Hodgkin lymphoma (NHL). In some embodiments, the subject is within a particular range of age, such as subjects that are 25 years or less of age, such as pediatric subjects.
    Type: Application
    Filed: November 15, 2019
    Publication date: January 13, 2022
    Applicant: Juno Therapeutics, Inc.
    Inventors: Nikolaus Sebastian TREDE, Tina ALBERTSON, Brian CHRISTIN, Rachel K. YOST, Michelle KANG, Ryan P. LARSON, Jeffrey TEOH
  • Publication number: 20220008477
    Abstract: The present disclosure relates in some aspects to methods, compositions and uses involving immunotherapies, such as adoptive cell therapy, e.g., T cell therapy, and an immunomodulatory compound, such as a structural or functional analog or derivative of thalidomide and/or an inhibitor of E3-ubiquitin ligase. The provided methods, compositions and uses include those for combination therapies involving the administration or use of one or more immunomodulatory compounds in conjunction with a T cell therapy, such as a genetically engineered T cell therapy involving cells engineered with a recombinant receptor, such as chimeric antigen receptor (CAR)-expressing T cells. Also provided are compositions, methods of administration to subjects, articles of manufacture and kits for use in the methods.
    Type: Application
    Filed: November 7, 2019
    Publication date: January 13, 2022
    Applicant: Juno Therapeutics, Inc.
    Inventors: Jens HASSKARL, Stanley R. FRANKEL, Michael PORTS, Michael POURDEHNAD, Heidi JESSUP, Yue JIANG, Jim Shi Xiang QIN, Neha SONI, Melissa WORKS
  • Publication number: 20210393690
    Abstract: Provided herein are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain plasma cell malignancy. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs) specific to B-cell maturation antigen (BCMA). In some embodiments, the methods are for treating subjects with multiple myeloma (MM). Also provided are genetically engineered cells containing such BCMA-binding receptors for uses in adoptive cell therapy.
    Type: Application
    Filed: October 31, 2019
    Publication date: December 23, 2021
    Applicants: Juno Therapeutics, Inc., Memorial Sloan Kettering Cancer Center
    Inventors: Blythe D. SATHER, Eric L. SMITH, Semih TAREEN, Aye CHEN, Cyr DE IMUS, Erik HESS, Audrey OLSHEFSKY, Stefan PONKO, Mariana Cota STIRNER
  • Publication number: 20210393689
    Abstract: Provided are chimeric antigen receptors (CARs), which contain antibody portions specific to G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D) and polynucleotides that encode CARs specific for GPRC5D. The disclosure further relates to genetically engineered cells, containing such GPRCSD-binding receptors, and uses thereof in adoptive cell therapy.
    Type: Application
    Filed: October 31, 2019
    Publication date: December 23, 2021
    Applicants: Juno Therapeutics, Inc., Memorial Sloan Kettering Cancer Center
    Inventors: Blythe D. SATHER, Eric L. SMITH, Cyr DE IMUS, Kimberly HARRINGTON, Jon JONES, Aye CHEN, Semih TAREEN, Erik HESS, Stefan PONKO, Audrey OLSHEFSKY, Carlos FERNANDEZ DE LARREA, Renier BRENTJENS
  • Publication number: 20210393691
    Abstract: The present disclosure provides cell populations enriched for CD57 negative T cells, or depleted for CD57 positive cells, and methods for stimulating, cultivating, expanding, and/or genetically engineering cell populations enriched for CD57? T cells or depleted for CD57+ T cells. Also included are methods for generating, isolating, enriching, or selecting CD57? T cells or depleting CD57+ cells, such as by negative selection.
    Type: Application
    Filed: November 5, 2019
    Publication date: December 23, 2021
    Applicant: Juno Therapeutics, Inc.
    Inventors: Sara COOPER, Daniel COSSETTE, Ryan LARSON, Jeffrey TEOH
  • Publication number: 20210363258
    Abstract: Provided are binding molecules, such as TCRs or antigen binding fragments thereof and antibodies and antigen-binding fragments thereof, such as those that recognize or bind human papilloma virus (HPV) 16, including HPV16 E6 and HPV16 E7. Also provided are engineered cells containing such binding molecules, compositions containing the binding molecules or engineered cells, and methods of treatment, such as administration of the binding molecules, engineered cells, or compositions.
    Type: Application
    Filed: July 23, 2021
    Publication date: November 25, 2021
    Applicant: Juno Therapeutics, Inc.
    Inventors: James SISSONS, Cameron Brandt, Alexandra Croft, Allen Ebens, Haley Peper, Dean Y. Toy
  • Publication number: 20210324100
    Abstract: Provided herein are chimeric receptors, such as chimeric antigen receptors (CARs), comprising BCMA-binding molecules, such as anti-BCMA antibodies and antigen-binding fragments thereof, such as heavy chain variable (VH) regions and single-chain antibody fragments, and encoding polynucleotides. In some embodiments, the anti-BCMA chimeric receptors specifically bind to BCMA. Among the anti-BCMA-binding molecules are human antibodies, including those that compete for binding to BCMA with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the CARs and uses thereof such as in adoptive cell therapy.
    Type: Application
    Filed: June 21, 2021
    Publication date: October 21, 2021
    Applicants: Juno Therapeutics, Inc., Memorial Sloan Kettering Cancer Center
    Inventors: Blythe D. SATHER, Eric L. SMITH, Rupesh AMIN, Aye CHEN, Kimberly HARRINGTON, Collin HAUSKINS, Erik HESS, Cyr DE IMUS, Jon JONES, Audrey OLSHEFSKY, Stefan PONKO, Ruth SALMON, Semih TAREEN, Rebecca WU, Yan CHEN, Steven M. SHAMAH, Csaba PAZMANY, Jui DUTTA-SIMMONS, Mariana Cota STIRNER, Melissa WORKS
  • Publication number: 20210284709
    Abstract: Provided are binding molecules, such as TCRs or antigen binding fragments thereof and antibodies and antigen-binding fragments thereof, such as those that recognize or bind human papilloma virus (HPV) 16, including HPV 16 E6 and HPV 16 E7. Also provided are engineered cells containing such binding molecules, compositions containing the binding molecules or engineered cells, and methods of treatment, such as administration of the binding molecules, engineered cells, or compositions.
    Type: Application
    Filed: September 28, 2018
    Publication date: September 16, 2021
    Applicants: Juno Therapeutics, Inc., Editas Medicine, Inc.
    Inventors: Cameron BRANDT, Brian BELMONT, Christopher BORGES, Stephen Michael BURLEIGH, Alexandra CROFT, Stephen Jacob GOLDFLESS, David Jeffrey HUSS, Yue JIANG, Timothy G. JOHNSTONE, David KOPPSTEIN, Hieu NGUYEN, Christopher Heath NYE, Haley PEPER, Blythe D. SATHER, Sonia TIMBERLAKE, Dean Y. TOY, Queenie VONG, Gordon Grant WELSTEAD, James SISSONS
  • Publication number: 20210254000
    Abstract: Provided herein are methods for producing engineered T cells that express a recombinant receptor, such as for use in cell therapy. In some aspects, the provided methods include one or more steps for incubating the cells under stimulating conditions, introducing a recombinant polypeptide to the cells through transduction or transfection, and/or cultivating the cells under conditions that promote proliferation and/or expansion, in which one or more steps is carried out in the presence of an agent that inhibits mammalian target of rapamycin (mTOR) activity. In some aspects, cultivation is performed in the presence of an agent that inhibits mammalian target of rapamycin (mTOR) activity. In some aspects, the provided methods produce genetically engineered T cells with improved persistence and/or anti-tumor activity in vivo.
    Type: Application
    Filed: November 1, 2018
    Publication date: August 19, 2021
    Applicants: Juno Therapeutics, Inc., Celgene Corporation
    Inventors: Archana BRAHMANDAM, Lucas James THOMPSON, Deborah MORTENSEN, Ellen FILVAROFF
  • Publication number: 20210255173
    Abstract: Provided herein are methods for assessing cell surface glycans, e.g., N-glycans, by assessing a sample of released surface glycans, and determining the presence, absence, or level of glycans present in the sample. Also provided are methods of assaying and/or evaluating a cell composition by assessing the cell surface glycan profile of the cell composition and comparing the profile to a reference sample. Methods for manufacturing and/or culturing a plurality of cell compositions having consistent surface glycan expression with low variability are also provided.
    Type: Application
    Filed: April 13, 2018
    Publication date: August 19, 2021
    Applicant: Juno Therapeutics, Inc.
    Inventors: Paul Ken KODAMA, Tom KOWSKI, Mirna MUJACIC, Kenneth Mayo PRENTICE
  • Publication number: 20210238309
    Abstract: Provided are ROR1 binding molecules, including anti-ROR1 antibodies, including antibody fragments such as variable heavy chain (VH) regions, single-chain fragments, and chimeric receptors including the antibodies, such as chimeric antigen receptors (CARs). In some embodiments, the antibodies specifically bind to ROR1. Among the antibodies are human antibodies, including those that compete for binding to ROR1 with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the chimeric receptors, and uses of the binding molecules and cells adoptive cell therapy.
    Type: Application
    Filed: December 14, 2020
    Publication date: August 5, 2021
    Applicant: Juno Therapeutics, Inc.
    Inventors: Yan CHEN, Steven M. SHAMAH, Csaba PAZMANY, Jui DUTTA-SIMMONS
  • Publication number: 20210230671
    Abstract: Provided are methods for assessing nucleic acid sequences integrated into a genome of a genetically engineered cell, such as a genetically engineered cell used in cell therapy. Cells are generally genetically engineered to express a recombinant protein, such as a recombinant receptor, via introduction of a polynucleotide and integration of certain sequences in the polynucleotide, such as recombinant sequences, into the genome of the cell. In some aspects, the provided methods can be used to distinguish integrated nucleic acids and non-integrated, residual nucleic acids.
    Type: Application
    Filed: August 9, 2019
    Publication date: July 29, 2021
    Applicant: Juno Therapeutics, Inc.
    Inventor: Adrian Wrangham BRIGGS
  • Patent number: 11072660
    Abstract: Provided are binding molecules, such as TCRs or antigen binding fragments thereof and antibodies and antigen-binding fragments thereof, such as those that recognize or bind human papilloma virus (HPV) 16, including HPV 16 E6 and HPV 16 E7. Also provided are engineered cells containing such binding molecules, compositions containing the binding molecules or engineered cells, and methods of treatment, such as administration of the binding molecules, engineered cells, or compositions.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: July 27, 2021
    Assignee: Juno Therapeutics, Inc.
    Inventors: James Sissons, Cameron Brandt, Alexandra Croft, Allen Ebens, Haley Peper, Dean Y. Toy
  • Patent number: 11066475
    Abstract: Provided herein are chimeric receptors, such as chimeric antigen receptors (CARs), comprising BCMA-binding molecules, such as anti-BCMA antibodies and antigen-binding fragments thereof, such as heavy chain variable (VH) regions and single-chain antibody fragments, and encoding polynucleotides. In some embodiments, the anti-BCMA chimeric receptors specifically bind to BCMA. Among the anti-BCMA-binding molecules are human antibodies, including those that compete for binding to BCMA with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the CARs and uses thereof such as in adoptive cell therapy.
    Type: Grant
    Filed: November 1, 2018
    Date of Patent: July 20, 2021
    Assignees: Juno Therapeutics, Inc., Memorial Sloan Kettering Cancer Center
    Inventors: Blythe D. Sather, Eric L. Smith, Rupesh Amin, Aye Chen, Kimberly Harrington, Collin Hauskins, Erik Hess, Cyr De Imus, Jon Jones, Audrey Olshefsky, Stefan Ponko, Ruth Salmon, Semih Tareen, Rebecca Wu, Yan Chen, Steven M. Shamah, Csaba Pazmany, Jui Dutta-Simmons, Mariana Cota Stirner, Melissa Works
  • Publication number: 20210207080
    Abstract: Provided herein is a serum-free media for culturing, such as cultivating, preparing and/or producing cells, such as immune cells, such as genetically engineered cells. Also provided is a liquid basal media and frozen supplements that can be used to produce serum-free media. The provided embodiments include methods for producing serum-free media and methods for culturing cells, such as activating, transducing, cultivating or expanded cells, in the presence of serum-free media.
    Type: Application
    Filed: December 7, 2018
    Publication date: July 8, 2021
    Applicant: Juno Therapeutics, Inc.
    Inventors: Pascal BEAUCHESNE, Kien KHUU-DUONG, Ivie AIFUWA, Calvin CHAN
  • Publication number: 20210198372
    Abstract: Provided are methods of treatment, such as methods involving administering and/or determining dosing of, cell therapy, such as of cells engineered with a recombinant receptor, such as a T cell receptor (TCR) or chimeric antigen receptor (CAR). In some embodiments, the methods include determining a therapeutic range and/or window for dosing, for example, based on the estimated probabilities of risk of developing a toxicity and estimated probabilities of a treatment outcome or response, such as treatment, reduction nor amelioration of a sign or symptom thereof, or degree or durability thereof, following administration of the cell therapy or engineered cells. In some aspects, the methods involve administering an agent capable of modulating the engineered cells. Also provided are methods of ameliorating and/or treating a toxicity.
    Type: Application
    Filed: November 30, 2018
    Publication date: July 1, 2021
    Applicant: Juno Therapeutics, Inc.
    Inventors: Tina ALBERTSON, Jacob Randolph GARCIA, Mark J. GILBERT, Jens HASSKARL, Mark D. HEIPEL, He LI, Claire L. SUTHERLAND, Nikolaus Sebastian TREDE
  • Publication number: 20210180014
    Abstract: Provided herein are reporter T-cells containing a reporter operably linked to the Nur77 locus. Also provided are methods for screening for an activity of a recombinant receptor, including those containing an extracellular antigen-binding domain and an intracellular signaling domain, such as a chimeric antigen receptor (CAR), including assessing activity of a cell expressing the recombinant receptor based on a detectable expression of a reporter molecule responsive to a signal through the intracellular signaling region of the recombinant receptor. In some embodiments, the activity assessed is an antigen-dependent or an antigen-independent activity. In some embodiments, the methods can be used to screen a plurality of reporter cells each containing a nucleic acid molecule encoding a candidate recombinant receptor, e.g. CAR, and assessing such cells for one or more property or activity. The methods can be high-throughput.
    Type: Application
    Filed: November 1, 2018
    Publication date: June 17, 2021
    Applicant: Juno Therapeutics, Inc.
    Inventors: Amin RUPESH, Aye CHEN
  • Publication number: 20210163893
    Abstract: The present disclosure provides processes for genetically engineering T cells, such as primary CD4+ T cells and/or CD8+ T cells, for use in cell therapy that does not involve expanding the cells. In particular aspects, the provided processes successfully generate compositions of engineered T cells, such as containing populations of engineered T cells, that express a chimeric antigen receptor (CAR) within a shortened amount of time as compared to alternative engineering processes, such as processes that involve expanding the cells. In certain aspects, the provided processes successfully generate a composition of engineered T cells suitable for use in cell therapy within 4 days from when the process to stimulate or activate the cells is initiated.
    Type: Application
    Filed: August 9, 2019
    Publication date: June 3, 2021
    Applicant: Juno Therapeutics, Inc.
    Inventors: Matthew WESTOBY, Adrian Wrangham BRIGGS, David G. KUGLER, Lothar GERMEROTH, Christian STEMBERGER, Mateusz Pawel POLTORAK, Divya VARUN, Keenan BASHOUR, Robert Guy CASPARY, Calvin CHAN
  • Publication number: 20210164062
    Abstract: Provided are methods of detecting replication competent virus, e.g., replication competent retrovirus such as gammaretrovirus or lentivirus, in a sample containing a cell transduced with a viral vector particle encoding a recombinant and or heterologous molecule, e.g., heterologous gene product. The methods may include assessing transcription of one or more target genes, such as viral genes, that are expressed in a retrovirus but not expressed in the viral vector particle. Replication competent retrovirus may be determined to be present if the levels of RNA of the one or more target genes is higher than a reference value, which can be measured directly or indirectly, including from a positive control sample containing RNA from the respective target gene at a known level and/or at or above the limit of detection of the assay.
    Type: Application
    Filed: January 31, 2019
    Publication date: June 3, 2021
    Applicant: Juno Therapeutics, Inc.
    Inventors: Ruth BERRY, Edwin WEBB
  • Patent number: 11020429
    Abstract: Provided are cells, e.g., engineered immune cells, expressing recombinant or engineered molecules involved in metabolic pathways, such as those that promote or inhibit one or more metabolic steps, reactions, or pathways, for example, in T cells. Such molecules include those that induce or repress a particular functional outcome or metabolic event, for example, one that promotes differentiation or reprogramming into a particular phenotypic state, such as memory, long-lived, activated or activatable, non-exhausted, phenotype or stem-like phenotype. The cells generally further express an immune receptor, such as an antigen receptor, which may be an engineered receptor, such as a CAR or recombinant TCR, or may be a natural immune receptor. Also provided are cells, such as T cells, expressing such molecules and combinations thereof, compositions comprising such cells, nucleic acids such as vectors encoding the same, and methods of administration to subjects in adoptive cell therapy.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: June 1, 2021
    Assignee: Juno Therapeutics, Inc.
    Inventor: Lucas James Thompson